Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C

Digestive Diseases and Sciences

Volumn 45, Issue 4, 2000, Pages 685-689

  Buti, Maria ^a,b   Olive, Gemma ^a,b   Stalgis, Carlos ^a,b   Esteban, Rafael ^a,b   Guardi, Jaime ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

HCV RNA; Hepatitis C; Interferon; Nonresponders; Quantification; Ribavirin

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034072162     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005479207106     Document Type: Article

References (19)

1. 1. Lindsay K: Therapy of hepatitis C: Overview. Hepatology 26:71c-77s, 1997
2. 2. Poynard T, Bedossa P, Chevallier M, et al: A comparison of three interferon α-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
3. 3. Carithers R, Emerson S: Therapy of hepatitis C: Meta-analysis of interferon α-2b trials. Hepatology 26:83s-88s, 1997
4. 4. Poynard T, Leroy V, Cohard M, et al: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 24:778-789, 1996
5. 5. Davis GL, Lau JY: Factors predictive of a beneficial response to therapy of Hepatitis C. Hepatology 26:122S-127S, 1997
6. 6. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A: Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison. Hepatology 26:1640-1645, 1997
7. 7. Martinot-Peignoux M, Marcellin P, Pouteau M, et al: Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22:1050-1056, 1995
8. 8. Zeuzem S, Lee JH, Franke A, et al: Quantification of the initial decline of serum Hepatitis C virus RNA and response to interferon alfa. Hepatology 27:1149-1156, 1998
9. 9. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26:226-231, 1997
10. 10. Poynard T, Marcellin P, Lee SS, et al: Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C. Lancet 352:1426-1432, 1998
11. 11. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485-1492, 1998
12. 12. Davis GL, Esteban-Mur R, Rustgi V, et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339:1493-1499, 1998
13. 13. Brouwer J, Nevens F, Michielsen P: What options are left when hepatitis C does not respond to interferon? Placebo-controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon. J Hepatol 21:17A, 1994
14. 14. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O: Combination treatment with interferon α-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 46:43-47, 1995
15. 15. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al: A pilot study of combination therapy with ribavirin plus interferon α for interferon α-resistant chronic hepatitis C. Gastroenterology 107:812-817, 1994
16. 16. Pol S: Ribavirin-interferon vs. Interferon (alfa 2b-IFN) alone in non-responders to α-2b IFN in chronic hepatitis C. Hepatology 24:356A, 1996
17. 17. Orito E, Mizokami M, Suzuki K, et al: Loss of serum HCV RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis. J Med Virol 44:410-414, 1994
18. 18. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI: Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647-1653, 1997
19. 19. Renault PF, Hoofnagle JH: Side effects of alpha interferon. Semin Liver Dis 9:273-277, 1989